NANOSONICS LIMITED — Director's Dealing 2013

Sep 8, 2013

==> picture [202 x 57] intentionally omitted <==

9 September 2013

Company Announcements Office Australian Securities Exchange

Appendix 3Y Change of Director’s Interest Notices

Attached are two Appendix 3Y- Change of Director’s Interest Notices in respect of changes in the relevant interests in securities held by Dr Ron Weinberger, CEO and Executive Director of Nanosonics and Mr Michael Kavanagh, Non-Executive Director.

Additional information about the nature of the changes in securities held by Dr Weinberger is provided below.

On 4 September Dr Weinberger sold a total of 859,672 Ordinary Shares that were held directly and indirectly. The sale of shares by Dr Weinberger was required to fund a pressing tax liability, arising from the exercise of options that were granted to him in 2007. The shares were successfully placed with three institutional buyers and a parcel of shares was taken up by Michael Kavanagh, incoming CEO and President of Nanosonics.

Following this sale Dr Weinberger continues to hold 29,881 shares in the Nanosonics Deferred Employee Share Plan, 200,000 options which are fully vested and 1,258,726 Performance Rights which have varying vesting conditions attached to them. Dr Weinberger remains strongly committed to Nanosonics and continues to be incentivised and aligned to the success of Nanosonics through his share and option holdings.

For more information please contact:

Ron Weinberger, CEO or McGregor Grant, CFO, on +612 8063 1600 Rebecca Wilson, Investor and media relations, Buchan Consulting on +613 9866 4722 / 0417 382 391

About Nanosonics

Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets.

Initial market applications are designed for the reprocessing of reusable medical instruments. The Company’s first product is designed to disinfect Ultrasound Transducers. In parallel with the commercialisation of this product, Nanosonics is also developing other medical applications and exploring opportunities for its proprietary technology in other industries.

For more information about Nanosonics please visit www.nanosonics.com.au

Nanosonics Limited ABN 11 095 076 896 Unit 24 566 Gardeners Road, Alexandria NSW 2015 Australia Tel: +61 2 8063 1600 Fax: +61 2 8063 1600 Email: info@nanosonics.com.au w: www.nanosonics.com.au

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Nanosonics Limited ABN 11 095 076 896

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Dr Ronald Peter Weinberger

Date of last notice 11 April 2013

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	a) Indirect Interest b) Direct Interest c) Indirect Interest d) Indirect Interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	a) Shares held under the Nanosonics Deferred Employee Share Plan b) Fully Paid Shares c) Options d) Performance Rights
Date of change	4 September 2013
No. of securities held prior to change	a) 165,742 Shares held under the Nanosonics Deferred Employee Share Plan b) 693,930 Fully Paid Shares c) 268,607 Options held in the Nanosonics Employee Share Option Plan d) 1,220,000 Performance Rights held in the Nanosonics Employee Share Option Plan.

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Class	a) Ordinary Shares b) Ordinary Shares c) Options d) Performance Rights
Number acquired	29,881 Ordinary Shares
Number disposed	859,672 Ordinary Shares
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$739,317.92
No. of securities held after change	a) 29,881 (Indirect) Shares held in the Nanosonics Deferred Employee Share Plan b) 238,726 (Indirect) Options held in the Nanosonics Employee Share Option Plan c) 1,220,000 (Indirect) Performance Rights held in the Nanosonics Employee Share Option Plan.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	1) Issue of Shares under the terms and conditions of the Nanosonics Deferred Employee Share Plan 2) Sale of Ordinary Shares. Refer to attached announcement for additional information.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?
If prior written clearance was provided, on what date was this provided?

Director: Dr Ronald Weinberger Date: 9 September 2013

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Nanosonics Limited ABN 11 095 076 896

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Michael Kavanagh
Date of last notice	6 December 2012

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.
Date of change	4 September 2013
No. of securities held prior to change	100,000
Class	Ordinary Shares, fully paid
Number acquired	50,000 Ordinary Shares
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$43,000.00
No. of securities held after change	150,000 Ordinary Shares, fully paid
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market purchase

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period? If prior written clearance was provided, on what date was this provided?

Director: Mr Michael Kavanagh Date: 9 September 2013

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011